Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters

Armin Stucki, Peter Gerber, Fernando Acosta, Marianne Cottagnoud, Philippe Cottagnoud, Armin Stucki, Peter Gerber, Fernando Acosta, Marianne Cottagnoud, Philippe Cottagnoud

Abstract

The penetration of telavancin was 2% into inflamed meninges and ca. 1 per thousand into noninflamed meninges after two intravenous injections (30 mg/kg of body weight). In experimental meningitis, telavancin was significantly superior to vancomycin combined with ceftriaxone against a penicillin-resistant pneumococcal strain. Against a methicillin-sensitive staphylococcal strain, telavancin was slightly but not significantly superior to vancomycin.

Figures

FIG. 1.
FIG. 1.
Mean (±standard deviation) serum (A) and CSF (B) concentrations of telavancin in rabbits following intravenous administration of 30 mg/kg at 0 and 4 h.

References

    1. Adam, D. 2002. Global antibiotic resistance in Streptococcus pneumoniae. J. Antimicrob. Chemother. 50(Suppl.):1-5.
    1. Dacey, R. G., and M. A. Sande. 1974. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob. Agents Chemother. 6:437-441.
    1. Doern, G. V., S. S. Richter, A. Miller, N. Miller, C. Rice, K. Heilmann, and S. Beekmann. 2005. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin. Infect. Dis. 41:139-148.
    1. Entenza, J. M., J. Vouillamoz, M. P. Glauser, and P. Moreillon. 1997. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1662-1667.
    1. Gerber, C. M., M. Cottagnoud, K. A. Neftel, M. G. Tauber, and P. Cottagnoud. 1999. Meropenem alone and in combination with vancomycin in experimental meningitis caused by a penicillin-resistant pneumococcal strain. Eur. J. Clin. Microbiol. Infect. Dis. 18:866-870.
    1. Jensen, A. G., F. Espersen, P. Skinhoj, V. T. Rosdahl, and N. Frimodt-Moller. 1993. Staphylococcus aureus meningitis. A review of 104 nationwide, consecutive cases. Arch. Intern. Med. 153:1902-1908.
    1. Kaplan, S. L. 2002. Management of pneumococcal meningitis. Pediatr. Infect. Dis. J. 21:589-591.
    1. Kaplan, S. L., and E. O. Mason, Jr. 2002. Mechanisms of pneumococcal antibiotic resistance and treatment of pneumococcal infections in 2002. Pediatr. Ann. 31:250-260.
    1. Kim, J. H., C. van der Horst, C. D. Mulrow, and G. R. Corey. 1989. Staphylococcus aureus meningitis: review of 28 cases. Rev. Infect. Dis. 11:698-706.
    1. King, A., I. Phillips, and K. Kaniga. 2004. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J. Antimicrob. Chemother. 53:797-803.
    1. Klugman, K. P. 1996. Epidemiology, control and treatment of multiresistant pneumococci. Drugs 52(Suppl. 2):42-46.
    1. Paris, M. M., S. M. Hickey, M. I. Uscher, S. Shelton, K. D. Olsen, and G. H. McCracken, Jr. 1994. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 38:1320-1324.
    1. Paris, M. M., O. Ramilo, and G. H. McCracken, Jr. 1995. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 39:2171-2175.
    1. Schlesinger, L. S., S. C. Ross, and D. R. Schaberg. 1987. Staphylococcus aureus meningitis: a broad-based epidemiologic study. Medicine (Baltimore) 66:148-156.
    1. Shaw, J. P., J. Seroogy, K. Kaniga, D. L. Higgins, M. Kitt, and S. Barriere. 2005. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49:195-201.
    1. Van Bambeke, F. 2004. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. 4:471-478.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe